U.S. Pharmacist Weekly News Update
January 8, 2020

ADA Endorses Second-Line
T2D Treatments for Patients
With CVD Risks

For type 2 diabetes (T2D) patients who have cardiovascular disease or are at high risk for it, an SGLT-2 inhibitor of GLP-1 RA should be considered as optimal treatment. That’s according to new guidelines from the American Diabetes Association, which said the decision should be made independent of hemoglobin A1C levels. Here is more information.


FDA Issues Warning About Breathing Difficulties With Gabapetinoid Use
Pharmacists have filled a lot of prescriptions for gabapentinoids in the last decade or so. That is why they might be especially alarmed by a new FDA drug-safety communication and medication-label change. Find out what increases the risk of serious breathing difficulties in users of the drugs.

Statin Usage Increases for Some When Managed by Pharmacists Versus Internists
Is pharmacist management of chronic disease therapy comparable to internal medicine providers? Find out how researchers determined that is the case with statin use in patients diagnosed with diabetes, with some patients actually more likely to receive appropriate treatment in the pharmacy group.

Obesity Appears to Impact Response to Some Antiarrhythmic Medications
Pharmacists should be very interested in a new study suggesting that obesity can affect response to drugs used to treat atrial fibrillation. Find out how researchers determined that patients with obesity had significantly greater recurrence of atrial fibrillation compared with those without obesity who received sodium channel blocker antiarrhythmic drugs.

Connect With U.S. Pharmacist
Facebook Twitter USP Google AppUSP Itunes App